Time-Kill Study of the Activity of Telithromycin against Macrolide-Resistant Streptococcus pneumoniae Isolates with 23S rRNA Mutations and Changes in Ribosomal Proteins L4 and L22

ABSTRACT By use of a time-kill methodology, the antipneumococcal activity of telithromycin was determined against macrolide-resistant S. pneumoniae isolates having mutations in the 23S rRNA gene and changes in the ribosomal proteins L4 and L22. Telithromycin had MICs ranging between 0.03 and 0.25 μg/ml and was bactericidal against four of seven strains after 24 h at two times the MIC.

[1]  K. Bush,et al.  In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides , 2005, Antimicrobial Agents and Chemotherapy.

[2]  Á. Soriano,et al.  Activity of telithromycin against erythromycin-susceptible and -resistant Streptococcus pneumoniae isolates from adults with invasive infections. , 2004, International journal of antimicrobial agents.

[3]  R. Reinert.  Clinical efficacy of ketolides in the treatment of respiratory tract infections. , 2004, The Journal of antimicrobial chemotherapy.

[4]  R. Lütticken,et al.  Ribosomal Mutations Conferring Resistance to Macrolides in Streptococcus pneumoniae Clinical Strains Isolated in Germany , 2003, Antimicrobial Agents and Chemotherapy.

[5]  R. Lütticken,et al.  Macrolide-Resistant Streptococcus pneumoniae and Streptococcus pyogenes in the Pediatric Population in Germany during 2000-2001 , 2003, Antimicrobial Agents and Chemotherapy.

[6]  D. Musher,et al.  Emergence of macrolide resistance during treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.

[7]  J. Kolman,et al.  Susceptibilities to Telithromycin and Six Other Agents and Prevalence of Macrolide Resistance Due to L4 Ribosomal Protein Mutation among 992 Pneumococci from 10 Central and Eastern European Countries , 2002, Antimicrobial Agents and Chemotherapy.

[8]  R. Lütticken,et al.  Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. , 2002, The Journal of antimicrobial chemotherapy.

[9]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .

[10]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[11]  M. Jacobs,et al.  Mutations in 23S rRNA and Ribosomal Protein L4 Account for Resistance in Pneumococcal Strains Selected In Vitro by Macrolide Passage , 2000, Antimicrobial Agents and Chemotherapy.

[12]  M. Jacobs,et al.  MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci , 1996, Antimicrobial agents and chemotherapy.

[13]  J. Sutcliffe,et al.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system , 1996, Antimicrobial agents and chemotherapy.

[14]  M. Jacobs,et al.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology , 1994, Antimicrobial Agents and Chemotherapy.

[15]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.